Pflug Koory LLC Sells 50 Shares of Stryker Co. (NYSE:SYK)
Pflug Koory LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 5.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 850 shares of the medical technology company’s stock after selling 50 shares during the quarter. Pflug Koory LLC’s holdings in Stryker were worth $178,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Raymond James Trust N.A. increased its stake in shares of Stryker by 1.8% during the fourth quarter. Raymond James Trust N.A. now owns 13,869 shares of the medical technology company’s stock worth $2,911,000 after purchasing an additional 240 shares during the period. First Command Bank lifted its holdings in shares of Stryker by 2,128.0% during the fourth quarter. First Command Bank now owns 1,671 shares of the medical technology company’s stock worth $351,000 after buying an additional 1,596 shares in the last quarter. Donaldson Capital Management LLC lifted its holdings in shares of Stryker by 9.6% during the fourth quarter. Donaldson Capital Management LLC now owns 3,872 shares of the medical technology company’s stock worth $813,000 after buying an additional 339 shares in the last quarter. Webster Bank N. A. boosted its position in shares of Stryker by 50.0% in the fourth quarter. Webster Bank N. A. now owns 300 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 100 shares during the period. Finally, PFG Advisors boosted its position in shares of Stryker by 11.4% in the fourth quarter. PFG Advisors now owns 10,803 shares of the medical technology company’s stock valued at $2,276,000 after acquiring an additional 1,107 shares during the period. 73.16% of the stock is owned by institutional investors and hedge funds.
Stryker stock traded up $1.07 during trading hours on Tuesday, reaching $207.96. 1,563,524 shares of the stock were exchanged, compared to its average volume of 1,137,823. The company has a current ratio of 2.18, a quick ratio of 1.35 and a debt-to-equity ratio of 0.64. Stryker Co. has a twelve month low of $157.43 and a twelve month high of $223.45. The company has a market cap of $78.43 billion, a P/E ratio of 28.45, a price-to-earnings-growth ratio of 2.34 and a beta of 0.76. The stock has a 50 day moving average of $206.80 and a two-hundred day moving average of $210.98.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.575 dividend. This represents a $2.30 dividend on an annualized basis and a yield of 1.11%. This is a boost from Stryker’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Monday, December 30th. Stryker’s dividend payout ratio (DPR) is 31.46%.
In other Stryker news, CEO Kevin Lobo sold 19,286 shares of the firm’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $215.71, for a total value of $4,160,183.06. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Timothy J. Scannell sold 4,666 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $206.28, for a total value of $962,502.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,318 shares of company stock valued at $6,706,338. Company insiders own 7.20% of the company’s stock.
A number of equities analysts recently commented on the stock. ValuEngine lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Robert W. Baird lifted their price objective on shares of Stryker from $239.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Piper Sandler downgraded shares of Stryker from an “overweight” rating to a “neutral” rating and set a $210.00 price objective for the company. in a report on Tuesday, January 7th. Evercore ISI upgraded shares of Stryker from an “in-line” rating to an “outperform” rating in a research report on Thursday, January 2nd. Finally, Canaccord Genuity raised their target price on shares of Stryker from $233.00 to $240.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $222.16.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: Monthly Dividend Stocks
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.